Last reviewed · How we verify
dihydroergotine mesylate sustained-release tablets
Dihydroergotine mesylate sustained-release tablets, developed by the Second Affiliated Hospital of Soochow University, are currently marketed but lack a specified primary indication or revenue data. The drug's key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. Without detailed trial results or identified competitors, the primary risk remains uncertain, but the patent expiry poses a significant long-term threat.
At a glance
| Generic name | dihydroergotine mesylate sustained-release tablets |
|---|---|
| Sponsor | Second Affiliated Hospital of Soochow University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: